Fatima Chunara
Remap Consulting UK
Fatima is an Associate Director at Remap Consulting and has extensive experience in the pharmaceutical industry. Within consultancy, Fatima has expertise in managing projects and supporting clients through their pricing and market access journey, particularly in navigating the UK healthcare landscape. Fatima also has experience at the National Institute for Health and Care Excellence (NICE) in England, where she was part of the technology appraisals team, providing technical leadership during the appraisal process.
Dr. Thomas Ecker
Ecker + Ecker GmbH, Hamburg
CEO;
Thomas Ecker is CEO of Ecker + Ecker. Since 2004 he has focused on HTA, Pricing and Reimbursement of pharmaceuticals. In that role he has been responsible for more than 100 G-BA submissions and price negotiations. His current focus is on EU HTA strategy and dossier development.
More information please click here.
Graham Foxon Ph.D. MBA
Remap Consulting GmbH, Cheshire, GREAT BRITAIN
Managing Director Graham co-founded Remap Consulting in 2014 with the mission to help clients optimise their pricing, health economics and market access outcomes. With over 20 years pharmceutical experience Graham brings unparalleled expertise in developing global product launch strategies and producing HTA submissions to adress payers' pricing and reimbursement requirements.
Andreas Schalueck
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH, München
Manager - Life Sciences
Marta Taboada Rodríguez
World Health Management, Madrid, Spain
Partner, Head of Market Access Department Pharmaceutical Industry 25 years of experience in health facilities and Hospital administration. 6 years of experience in Market Access and Institutional Relations (RIMA).
Dr Entela Xoxi
UNIVERSITÀ CATTOLICA del Sacro Cuore - Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS)
Lecturer with Collaboration Agreement for Research Projects, Senior Scientific Advisor - Independent consultant
10-11/12/2024
10-11/12/2024
10 December 2024: 9:00 am - 3:00 pm
11 December 2024: 9:00 am - 3:00 pm
online
online
Event - 1,590 € plus tax
The participation fee includes downloadable documentation, a certificate, access to the Learning Space and technical support including PreMeeting.
Event - 1,590 € plus tax
The participation fee includes downloadable documentation, a certificate, access to the Learning Space and technical support including PreMeeting.
Leila Grupp
Team Leader Pharma & Healthcare
+49 6221 500-695
l.grupp@forum-institut.de
Online seminar on Market Access & Pricing in Europe - this is how you can gain access as a pharmaceutical manufacturer!
Market access and pricing for drugs is complex and requires careful preparation for launch. Knowledge of the underlying health systems and the different, mutually influencing pricing systems in Europe is essential for it.
In our online seminar you will receive the most important information for successful market access in the EU4 countries and in the UK.
10th December 2024: Payer archetypes, Market Access and Pricing in France and the UK
11th December 2024: Market Access and Pricing in Spain, Germany and Italy
By attending the seminar...
09:00 Introduction
09:15
Andreas Schalueck
10:15 break
10:30
Graham Foxon Ph.D. MBA
12:15 Lunch break
13:15
Fatima Chunara, Graham Foxon Ph.D. MBA
15:00 End of day 1
09:00 Start of day 2
09:00
Marta Taboada Rodríguez
10:45 break
11:00
Dr Entela Xoxi
12:30 Lunch break
13:30
Dr. Thomas Ecker
15:00 End of seminar
of 5 stars of all ratings from 2023
of 5 stars on Trustpilot = good
This seminar will focus on AMNOG and JCA dossier preparation as well as the German AMNOG procedure in comparison with th...
This course familiarises you with regulatory post-approval duties and provides first-hand information on variation submi...
Do you want to independently plan and conduct pharmacovigilance audits? Then take this opportunity to become an "Auditor...
Outsourcing of activities, tasks or positions in regulatory affairs and pharmacovigilance is often standard practice. In...
- GVP Module XVI Risk minimisation measures (Rev 3) came into force - Do you already have a good understanding of PSUR a...